Clinical features of generalized lipodystrophy in Turkey: A cohort analysis

Archive ouverte

Yildirim Simsir, Ilgin | Tuysuz, Beyhan | Ozbek, Mehmet Nuri | Tanrikulu, Seher | Celik Guler, Merve | Karhan, Asuman Nur | Denkboy Ongen, Yasemin | Gunes, Nilay | Soyaltin, Utku Erdem | Altay, Canan | Nur, Banu | Ozalkak, Servan | Akgun Dogan, Ozlem | Dursun, Fatma | Pekkolay, Zafer | Eren, Mehmet Ali | Usta, Yusuf | Ozisik, Secil | Ozgen Saydam, Basak | Adiyaman, Suleyman Cem | Unal, Mehmet Cagri | Gungor Semiz, Gokcen | Turan, Ihsan | Eren, Erdal | Kayserili, Hulya | Jeru, Isabelle | Vigouroux, Corinne | Atik, Tahir | Onay, Huseyin | Ozen, Samim | Arioglu Oral, Elif | Akinci, Baris

Edité par CCSD ; Wiley -

International audience. Abstract Aim To describe the Turkish generalized lipodystrophy (GL) cohort with the frequency of each complication and the death rate during the period of the follow‐up. Methods This study reports on 72 patients with GL (47 families) registered at different centres in Turkey that cover all regions of the country. The mean ± SD follow‐up was 86 ± 78 months. Results The Kaplan–Meier estimate of the median time to diagnosis of diabetes and/or prediabetes was 16 years. Hyperglycaemia was not controlled in 37 of 45 patients (82.2%) with diabetes. Hypertriglyceridaemia developed in 65 patients (90.3%). The Kaplan–Meier estimate of the median time to diagnosis of hypertriglyceridaemia was 14 years. Hypertriglyceridaemia was severe (≥ 500 mg/dl) in 38 patients (52.8%). Seven (9.7%) patients suffered from pancreatitis. The Kaplan–Meier estimate of the median time to diagnosis of hepatic steatosis was 15 years. Liver disease progressed to cirrhosis in nine patients (12.5%). Liver disease was more severe in congenital lipodystrophy type 2 (CGL2). Proteinuric chronic kidney disease (CKD) developed in 32 patients (44.4%) and cardiac disease in 23 patients (31.9%). Kaplan–Meier estimates of the median time to diagnosis of CKD and cardiac disease were 25 and 45 years, respectively. Females appeared to have a more severe metabolic disease, with an earlier onset of metabolic abnormalities. Ten patients died during the follow‐up period. Causes of death were end‐stage renal disease, sepsis (because of recurrent intestinal perforations, coronavirus disease, diabetic foot infection and following coronary artery bypass graft surgery), myocardial infarction, heart failure because of dilated cardiomyopathy, stroke, liver complications and angiosarcoma. Conclusions Standard treatment approaches have only a limited impact and do not prevent the development of severe metabolic abnormalities and early onset of organ complications in GL.

Consulter en ligne

Suggestions

Du même auteur

Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes

Archive ouverte | Gautheron, Jérémie | CCSD

International audience. Background: Thymidine phosphorylase (TP), encoded by the TYMP gene, is a cytosolic enzyme essential for the nucleotide salvage pathway. TP catalyzes the phosphorylation of the deoxyribonucleo...

Biallelic CAV1 null variants induce Congenital Generalized Lipodystrophy with achalasia Short title: CAV1, generalized lipodystrophy and achalasia

Archive ouverte | Karhan, Asuman Nur | CCSD

International audience. Objective : CAV1 encodes caveolin-1, a major protein of plasma membrane microdomains called caveolae, involved in several signalling pathways. Caveolin-1 is also located at the adipocyte lipi...

European lipodystrophy registry: background and structure

Archive ouverte | von Schnurbein, Julia | CCSD

International audience. Abstract Background Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional dep...

Chargement des enrichissements...